One takeaway from this 12 months’s surge of biotech IPO exercise is that traders need to see at the least some scientific knowledge earlier than an organization makes its inventory market debut. Braveheart Bio has mid-stage trial outcomes indicating its lead cardiovascular drug may have a aggressive edge over commercialized medicines from Bristol Myers Squibb and Cytokinetics, and in a giant week for biotech IPOs, the younger firm pulled off the largest one.
Braveheart’s $382 million IPO topped upsized inventory new inventory issuances from immunology biotech Attovia Therapeutics, ache drug developer Latigo Biotherapeutics, and most cancers therapies firm BlossomHill Therapeutics. All 4 completed the week buying and selling at or above their IPO costs.
IPOs is available in cycles. Throughout the pandemic, IPOs for biotech firms, lots of them early stage and even preclinical, reached document ranges. Within the years since, there have been firm shutdowns and consolidations, Matt Phipps, companion and group head, biotechnology analysis, at William Blair, stated throughout a panel dialogue on the MedCity Information Bullseye occasion in Chicago in late July. He added that traders think about preclinical stage too early for an organization to go public, and the present IPO market extra intently resembles 2017, when biotechs eyeing IPOs had some scientific knowledge.
“Now I believe we’re again to what appears a bit bit more healthy of at the least having some proof of idea [data], even when it’s Section 1,” Phipps stated.
Chris Garabedian, chairman and CEO of Xontogeny, stated the stronger IPO exercise of 2026 tracks with different robust monetary indicators. Biotech financings have returned and M&A exercise is on observe to succeed in document ranges, he stated throughout the panel. The biotech IPO market of 2026 extra intently resembles that of 2017.
“Firms that did handle to safe a Sequence B to get them into the clinic or get scientific knowledge — that’s what we see on this pent-up [IPO] demand,” Garabedian stated. “These had been the businesses that, throughout that 5 years, they couldn’t go public, however they had been in a position to get personal capital, and so they had knowledge, and so they had been additional alongside, and it was not the kind of IPO that we noticed in 2020, 2021.”
Of the 4 biotechs that went public this previous week, Attovia, Latigo, and BlossomHill match the profile Garabedian described. All three had been based within the pandemic years and raised personal rounds of financing to advance their applications to the clinic. Braveheart is a a lot newer firm, going public practically a 12 months after licensing from Hengrui Pharma what’s now its lead program. However Braveheart nonetheless suits the profile of 2026 biotech IPOs in that it has knowledge to point out traders to de-risk the funding.
Braveheart’s BHB-1893 is an oral small molecule in improvement for obstructive hypertrophic cardiomyopathy (HCM), a cardiovascular dysfunction by which thickening coronary heart muscle makes it more durable for the organ to pump blood, probably progressing to coronary heart failure. The thickening develops from extreme exercise of a cardiac protein referred to as myosin. BHB-1893 is a small molecule myosin inhibitor.
Obstructive HCM is at the moment treatable with two myosin inhibitors. BMS was first with Camzyos, which was accredited in 2022 and entered blockbuster gross sales territory in 2025. Late final 12 months, the FDA accredited Myqorzo, a myosin inhibitor developed by Cytokinetics. The labels of each merchandise carry black field warnings for cardiovascular dangers. The approvals of each medication additionally require a mitigation program that informs prescribers and sufferers about the best way to monitor and handle these dangers, although analysts view this system for the Cytokinetics drug as much less restrictive.
In an interview final 12 months, Braveheart CEO Travis Murdoch stated his firm licensed the Hengrui drug after seeing encouraging Section 1 and Section 2 knowledge indicating it may have a security edge and less complicated dose titration. In Could, Hengrui and Braveheart introduced preliminary Section 2 knowledge for the drug in non-obstructive HCM, which is much less widespread than obstructive HCM. It’s a sign with no FDA-approved therapies and one the place the Bristol drug failed. In the meantime, BHB-1893’s Section 3 outcomes confirmed enhancements throughout numerous measures cardiac measures together with favorable tolerability. Within the IPO submitting, Braveheart stated it’s making ready for international Section 3 exams of BHB-1893 in each obstructive HCM and non-obstructive HCM.
“Our objective is to enhance the remedy choices for sufferers with HCM and different cardiovascular illnesses,” Braveheart stated within the submitting. “We imagine BHB 1893 can meaningfully enhance upon first era [cardiac myosin inhibitors] and tackle key limitations equivalent to velocity of onset, depth of gradient response, systolic security, reversibility, and prescribing complexity.”
Braveheart plans to spend about $90 million to advance BHB-1893 by way of the completion of a Section 3 check in obstructive HCM. This trial is predicted to begin within the second half of this 12 months; preliminary knowledge are anticipated within the second half of subsequent 12 months. One other $100 million is budgeted for Section 3 testing of this drug in non-obstructive HCM, a trial anticipated to start within the first half of 2027.
Braveheart set preliminary monetary phrases of 18.75 million shares provided within the vary of $15 to $17 every. Final Wednesday, the corporate ended up providing 21.25 million shares priced at $18 every, elevating $382.5 million. Braveheart’s shares closed Friday at $30 every, ending their first week on the Nasdaq up greater than 66% from the IPO worth. After Friday’s market shut, Braveheart introduced that underwriters exercised their choice to buy extra shares, bringing the biotech’s complete monetary haul to $439.9 million.
Photograph: Getty Pictures